Ameritas Investment Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Ameritas Investment Partners’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$184K	Buy	10,828 +1,099	+11%	+$17.6K	﹤0.01%	1445
2026 Q1	$144K	Hold	9,729	–	–	﹤0.01%	1459
2025 Q4	$155K	Hold	9,729	–	–	﹤0.01%	1415
2025 Q3	$108K	Sell	9,729 -2,297	-19%	-$25.1K	﹤0.01%	1645
2025 Q2	$102K	Sell	12,026 -1,428	-11%	-$11.4K	﹤0.01%	1748
2025 Q1	$108K	Hold	13,454	–	–	﹤0.01%	1650
2024 Q4	$121K	Hold	13,454	–	–	﹤0.01%	1646
2024 Q3	$98.6K	Hold	13,454	–	–	﹤0.01%	1801
2024 Q2	$76.8K	Hold	13,454	–	–	﹤0.01%	1895
2024 Q1	$67.4K	Hold	13,454	–	–	﹤0.01%	1975
2023 Q4	$121K	Hold	13,454	–	–	﹤0.01%	1608
2023 Q3	$105K	Buy	13,454 +2,271	+20%	+$22.2K	﹤0.01%	1628
2023 Q2	$108K	Buy	11,183 +1,122	+11%	+$11.6K	﹤0.01%	1542
2023 Q1	$110K	Hold	10,061	–	–	﹤0.01%	1473
2022 Q4	$83.4K	Hold	10,061	–	–	﹤0.01%	1728
2022 Q3	$75K	Hold	10,061	–	–	﹤0.01%	1698
2022 Q2	$101K	Buy	+10,061	New	+$112K	﹤0.01%	1503

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameritas Investment Partners's AUPH Position: Q2 2026 in Review

Ameritas Investment Partners increased its Aurinia Pharmaceuticals (AUPH) stake by 11% in Q2 2026, buying an estimated $17.6K and bringing the position to 10,828 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #1445.

Ameritas Investment Partners first reported a position in AUPH in Q2 2022 and has held it in 17 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Ameritas Investment Partners held 10,828 shares of Aurinia Pharmaceuticals worth $184K as of Q2 2026.
Ameritas Investment Partners bought 1,099 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $17.6K.
Aurinia Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1445 holding.
Ameritas Investment Partners first reported a position in Aurinia Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.